SELLAS Reports Promising Updated Clinical Data and Initial Immune Response Profiles from Ongoing Phase 1/2 Study of Galinpepimut-S (GPS) Combined with Keytruda for Treating WT1+ Advanced Ovarian Cancer

Frank Burrell
Scientific Storytelling

Daniel Sontupe
Market Access

Paul Theisen
Patient Acquisition

Bud Bilanich
Success Coach

Matthew Durham
Omnidynamic Marketing

Suma Ramadas, PhD
Medical Affairs

Amy Giles
Increasing Engagement

Brenda Snow
Authentic Patient Voice

Stacey Gandler
Brand Nourishment

David Linetsky
Point-of-Care Marketing

Matt Turner
Patient Affordability

Liz Kane
Impactful Strategy

Joey Cohen
Medication Adherence

Pat Purcell
Meeting Engagement